Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following conditions and symptoms are excluded:
• •Less than 2 weeks since major surgery.
• •Serious uncontrolled infection. NOTE:
• •Must be ruled out by thorough work-up in patients with unexplained fevers, night sweats, or involuntary weight loss of more than 10% normal weight.
• •Leukopenia.
• •Thrombocytopenia.
• •Patients with the following prior conditions are excluded:
• •History of angina or myocardial infarction within the past 6 months.
• •Second degree or third degree atrioventricular block without a pacemaker.
• •Congestive heart failure (poorly controlled).
• •History of prior malignancy except:
• •Completely excised in situ, carcinoma of the cervix or nonmelanomatous skin cancer.
• •Curatively treated other malignancy with no evidence of disease for at least 5 years.
• •Prior Medication:
• •Excluded:
• •Prior taxane therapy.
• •Required:
• •At least one systemic chemotherapy regimen that failed to maintain significant benefit. NOTE:
• •Intralesional chemotherapy regimens are not considered as prior chemotherapy.
• •At least 2 weeks since last dose of prior systemic chemotherapy.